Mogamulizumab-kpkc - Biologic Drug Details

Summary for mogamulizumab-kpkc

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for mogamulizumab-kpkc

Mechanism of Action	Chemokine Receptor Type 4 Interactions
Established Pharmacologic Class	Chemokine Receptor Type 4 Interaction Monoclonal Antibody
Chemical Structure	Antibodies, Monoclonal

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for mogamulizumab-kpkc Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for mogamulizumab-kpkc Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for mogamulizumab-kpkc Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Mogamulizumab-kpkc

Last updated: February 20, 2026

What is Mogamulizumab-kpkc?

Mogamulizumab-kpkc (brand name: Poteligeo) is a humanized monoclonal antibody targeting CCR4. It is approved for cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides, as well as adult T-cell leukemia-lymphoma (ATLL). Approved by the FDA in August 2018, the drug is marketed by Kyowa Kirin.

Market Penetration and Prescriptions

As of 2023, mogamulizumab-kpkc remains a niche therapy. The drug's uptake has been limited to specific hematological indications. The key drivers include:

• Regulatory approvals: FDA approval in 2018, with additional approvals in Japan, Europe, and other markets.
• Clinical adoption: Limited to patients with relapsed or refractory CTCL or ATLL.
• Physician familiarity: Adoption constrained by the narrow indication and competition from other biologics.

In the U.S., annual prescriptions are estimated at approximately 2,000 to 3,000 patients, representing less than 10% of the eligible patient population with CTCL or ATLL.

Competitive Landscape

Mogamulizumab-kpkc faces competition from:

• Skin-directed therapies: Topical corticosteroids, phototherapy.
• Systemic agents: Chemotherapies and targeted agents like brentuximab vedotin.
• Other biologics and immunotherapies: Limited competition for CCR4 targets.

Key competitors include brentuximab vedotin (Adcetris), which has broader approval for systemic CTCL, and emerging approaches like PDE3 inhibitors.

Pricing and Revenue Estimations

The approved wholesale acquisition cost (WAC) for mogamulizumab-kpkc is approximately $8,000 per infusion. Typical treatment involves 8 infusions over 49 to 98 weeks, depending on response.

• Annual revenue estimates:

Parameter	Value
Average annual patient treatments	1,200–2,400 (US)
Price per infusion	$8,000
Infusions per patient per year	4–8
Estimated US revenue	$38.4 million – $153.6 million

Worldwide revenues are constrained by market access, reimbursement, and clinical adoption, with global sales likely below $200 million annually.

Regulatory and Reimbursement Considerations

• Regulatory status: Approved in North America, Europe, and Japan primarily for skin lymphomas.
• Reimbursement: Varies by payer; high-cost pricing limits access in some markets.
• Market expansion: Pending approval for additional indications; ongoing clinical trials may broaden the footprint.

Financial Trajectory and Growth Outlook

Mogamulizumab-kpkc's revenue is expected to grow modestly over the next five years, driven by:

• Increased clinical adoption within its approved indications.
• Potential label expansions based on clinical trial results.
• Elevated awareness in hematological malignancies with unmet needs.

However, slow uptake and competitive pressures limit rapid revenue growth. Cumulative global sales could reach approximately $500 million over the next five years if market expansion and pricing strategies are favorable.

Key Drivers and Risks

Drivers	Risks
Evolving clinical guidelines	Market size constraints due to narrow approved indications
New indications or combination therapies	Competition from emerging treatments or biosimilars
Reimbursement policies	Pricing pressures and access barriers

Summary

Mogamulizumab-kpkc's market is characterized by niche clinical use, limited patient population, and competitive therapies. It generates modest revenues with slow growth potential unless expanded into new indications or adopted more broadly.

Key Takeaways

• Approved for specific hematologic T-cell lymphomas with limited market penetration.
• Estimated US revenues between $38 million and $154 million annually.
• Future growth depends on label expansion, clinical adoption, and reimbursement landscape.
• Competition from broader-acting biologics and emerging therapies constrains potential upside.
• Market expansion opportunities exist but require successful clinical and regulatory outcomes.

FAQs

1. What factors limit mogamulizumab-kpkc's market size?
Its approval is restricted to specific T-cell malignancies, limiting the patient population. Competitive therapies also reduce uptake.

2. What is the primary revenue driver for mogamulizumab-kpkc?
The drug's price per infusion and the number of annual infusions per patient determine revenue, with US estimates around $100 million annually.

3. Are there plans for label expansion?
Ongoing clinical trials aim to assess efficacy in broader indications, potentially extending its market.

4. How does reimbursement affect its sales?
High treatment costs and variable payer coverage limit patient access, impacting overall revenue.

5. How does mogamulizumab-kpkc compare to similar therapies?
It offers targeted action against CCR4 but faces competition from broader systemic therapies and emerging immunotherapies.

---

References

[1] U.S. Food and Drug Administration. (2018). FDA approves Kyowa Kirin’s Poteligeo for cutaneous T-cell lymphoma.
[2] Kyowa Kirin. (2023). Mogamulizumab-kpkc prescribing information.
[3] IQVIA. (2023). U.S. Prescription Trends for Hematologic Malignancies.
[4] European Medicines Agency. (2018). Marketing authorization for Mogamulizumab.
[5] ClinicalTrials.gov. (2023). Ongoing clinical trials involving Mogamulizumab-kpkc.